Article ; Online: A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
2020 Volume 105, Issue 9, Page(s) 2335–2340
Abstract: Rendering coagulation factor X sensitive to thrombin was proposed as a strategy that can bypass the need for factor VIII. In this paper, this non-replacement strategy was evaluated in vitro and in vivo in its ability to correct factor VIII but also ... ...
| Abstract | Rendering coagulation factor X sensitive to thrombin was proposed as a strategy that can bypass the need for factor VIII. In this paper, this non-replacement strategy was evaluated in vitro and in vivo in its ability to correct factor VIII but also factor IX, X and XI deficiencies. A novel modified factor X, named Actiten, was generated and produced in the HEK293F cell line. The molecule possesses the required post-translational modifications, partially keeps its ability to be activated by RVV-X, factor VIIa/tissue factor, factor VIIIa/factor IXa and acquires the ability to be activated by thrombin. The potency of the molecule was evaluated in respective deficient plasmas or hemophilia A plasmas, for some with inhibitors. Actiten corrects dose dependently all the assayed deficient plasmas. It is able to normalize the thrombin generation at 20 μg/mL showing however an increased lagtime. It was then assayed in a rabbit antibody-induced model of hemophilia A where, in contrast to recombinant factor X wild-type, it normalized the bleeding time and the loss of hemoglobin. No sign of thrombogenicity was observed and the generation of activated factor X was controlled by the anticoagulation pathway in all performed coagulation assays. This data indicates that Actiten may be considered as a possible non replacement factor to treat hemophilia's with the advantage of being a zymogen correcting bleedings only when needed. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Animals ; Factor IX ; Factor VIII/genetics ; Factor VIIa ; Factor X/genetics ; Hemophilia A/drug therapy ; Hemophilia A/genetics ; Rabbits ; Thrombin | |||||
| Chemical Substances | Factor VIII (9001-27-8) ; Factor IX (9001-28-9) ; Factor X (9001-29-0) ; Factor VIIa (EC 3.4.21.21) ; Thrombin (EC 3.4.21.5) | |||||
| Language | English | |||||
| Publishing date | 2020-09-01 | |||||
| Publishing country | Italy | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 2333-4 | |||||
| ISSN | 1592-8721 ; 0017-6567 ; 0390-6078 | |||||
| ISSN (online) | 1592-8721 | |||||
| ISSN | 0017-6567 ; 0390-6078 | |||||
| DOI | 10.3324/haematol.2019.219865 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Uh III Zs.76: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.